You searched for Cystic fibrosis

News and Trends 20 Jun 2023

Anoat raises funds to tackle cystic fibrosis

Anoat Therapeutics, a French preclinical stage biotechnology company specialized in cystic fibrosis (CF), has raised €2 million ($2.17 million) in seed funding from AdBio partners. Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate. Anoat Therapeutics’ goal is to bring a transformative and mutation-agnostic […]

June 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

Renexxion goes to FDA with cystic fibrosis drug

Renexxion Ireland Limited has opened an investigational new drug (IND) application with the U.S Food and Drug Administration (FDA) for naronapride for the treatment of GI motility disorders in patients with cystic fibrosis (CF). This is a first step towards conducting clinical trials of the drug candidate in CF patients. Naronapride, post approval, could be […]

January 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

FDA gives ok to Krystal Biotech cystic fibrosis clinical trial

U.S. company Krystal Biotech is set to start a clinical trial for cystic fibrosis after the United States Food and Drug Administration (FDA) accepted its investigational new drug (IND) application. The gene therapy company will be evaluating KB407, a modified HSV-1 vector carrying two copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 22 Jun 2022

Cystic fibrosis in the crosshairs as Carbon Biosciences launches with $38M funding

Carbon Biosciences, a Longwood Fund founded biotech company developing parvovirus-derived gene therapies, has launched with $38 million of financing led by Agent Capital. Agent is joined by Longwood Fund, Astellas Venture Management LLC, the Cystic Fibrosis Foundation, Solasta Ventures, University of Tokyo Innovation Platform (UTokyoIPC), and Camford Capital. Massachusetts-based Carbon is harnessing novel parvovirus vectors […]

June 22, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 22 Mar 2022

Biotechs Carve out Niches in Cystic Fibrosis Treatment Space

Cystic fibrosis has proved resistant to treatments that provide long-lasting respite from the sticky mucus that affects the lungs and other organs. Emerging biotechs such as Kither Biotech as well as the old guard including Vertex are finding new ways to tackle the inherited disease. Cystic fibrosis is best known for causing thick mucus in […]

March 22, 2022 - 5 minutesmins - By Anita Chakraverty

In Depth 22 Nov 2021

How Will We Be Treating Cystic Fibrosis 10 Years From Now?

Current treatments for cystic fibrosis are not suitable for all patients and have a limited effect on this life-threatening disease. But new advances in the field promise to overcome these hurdles. The cause of cystic fibrosis is very straightforward. Its treatment, however, is not. People diagnosed with cystic fibrosis have a mutation in a gene […]

November 22, 2021 - 9 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Jan 2020

Update: CARB-X Grants Antabio Additional €4M to Develop Cystic Fibrosis Antibiotic

Update (03/01/2020): The global non-profit partnership CARB-X has awarded Antabio €4M ($4.4M) as a second grant installment funding development of a novel antibiotic for use against Pseudomonas infections in patients with cystic fibrosis. This is the second installment of a grant worth up to €7.6M awarded to Antabio in 2017. The French biotech was awarded […]

January 3, 2020 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Aug 2018

New Gene Therapy Could Treat Cystic Fibrosis With One Dose

A new partnership in the UK will develop a gene therapy for cystic fibrosis that could treat the disease with a single dose. Cystic fibrosis is a genetic disease that causes mucus to build up in a patient’s lungs. As a result, patients suffer from blocked airways and bacterial infections. While treatment advances have increased […]

August 6, 2018 - 3 minutesmins - By Alexander Burik

Interview 12 Mar 2018

A Dutch Company on the Quest Against Cystic Fibrosis

ProQR is the result of a personal quest against cystic fibrosis started by its CEO, Daniel de Boer. Interested in his story and the company’s unique approach to treating the disease using RNA technology, I decided to speak with him. Daniel de Boer founded ProQR in 2012 following a strong determination to improve the lives […]

March 12, 2018 - 6 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Mar 2018

London Biotech Uses Unique Double Mechanism of Action to Treat Cystic Fibrosis

Verona Pharma obtained positive Phase IIa trial results for a unique cystic fibrosis drug that inhibits two disease-related enzymes simultaneously, showing promise for treating a high unmet patient need. Verona Pharma, based in London, UK, aims to improve the lives of people with chronic respiratory diseases. Verona states their Phase IIa data provide grounds to […]

March 2, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 14 Dec 2017

A Breath of Fresh Air for Biotechs Working on Cystic Fibrosis Therapies?

Researchers from the University of Zurich have determined the structure of a chloride channel, which could be a target for new drugs to treat cystic fibrosis. Researchers at the University of Zurich have found a new target for future cystic fibrosis treatments. The study, published in Nature, has uncovered the structure of a protein that could help to […]

December 14, 2017 - 3 minutesmins - By Alex Dale

News and Trends 22 Nov 2017

Galapagos Cystic Fibrosis Drug Enters Phase I, Triggering €8.5M Payout

Galapagos will receive a $10M (€8.5M) milestone payment from its collaborator, AbbVie, after their cystic fibrosis candidate started a Phase I trial. Galapagos is a clinical-stage biotech developing small molecule medicines for a range of indications. It partnered up with the global pharma company, AbbVie, back in 2013, to develop a number of cystic fibrosis (CF) candidates for a […]

November 22, 2017 - 3 minutesmins - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us